Novel antifungal drugs

Current Opinion in Microbiology

Volumn 2, Issue 5, 1999, Pages 509-515

  Didomenico, Beth ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DIFLUOROPHENYL) 3 [4 [4 [2 (4 TRIFLUOROMETHOXYBENZYL) 2H 1,2,4 TRIAZOL 3 ONE 4 YL]PHENYL]PIPERAZIN 1 YL] 1 (1H 1,2,4 TRIAZOL 1 YL)BUTAN 2 OL; ALBACONAZOLE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICONAZOLE; NIKKOMYCIN; NYSTATIN; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; RAVUCONAZOLE; TERBINAFINE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIMICROBIAL THERAPY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG SPECIFICITY; DRUG TARGETING; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; REVIEW;

EID: 0032832199     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1369-5274(99)00009-0     Document Type: Review

References (92)

1. Sobel JD Candida glabrata - yet another emerging pathogen. Abstracts of the 38th Annual Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27, San Diego, CA. 1998;478 American Society for Microbiology, Washington DC.
2. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, Brandt ME, Hajjeh RA Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Abstracts of the 38th Annual Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27, San Diego, CA. 1998;483 American Society for Microbiology, Washington DC.
3. Pfaller MA, Jones RN, Doern GV, Sader HS, Hollis RJ, Messer SA International surveillance of blood stream infection due to Candida species: frequency of occurrence and antifungal susceptibility in the SENTRY program, Unites States, Canada, and South America, 1997. Abstracts of the 38th Annual Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27, San Diego, CA. 1998;483 American Society for Microbiology, Washington DC.
4. Nakagawa Z, Nucci M, Branchini ML, Salomao R, Richtmann R, Colombo AL In vitro susceptibility patterns of 200 recent bloodstream isolates of Candida species to four antifungal drugs determined by the NCCLS microbroth procedure. Abstracts of the 38th Annual Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27, San Diego, CA. 1998;488 American Society for Microbiology, Washington DC.
5. Koltin Y, Hitchcock CA The search for new triazole antifungal agents. Curr Opin Chem Biol. 1:1997;176-182.
6. Georgopapapdakou NH Antifungals: mechanism of action and resistance, established and novel drugs. Curr Opin Microbiol. 1:1998;547-557. An excellent review that discusses both the mode of action and resistance for a number of established and emerging antifungals.
7. Piscitelli SC, Walsh TJ: Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds and putative targets for antifungal drug development , vol 44. New York: Academic Press; 1998. A very detailed review of clinically used agents that also described pharmokinetics and drug-drug interactions.
8. Viviani MA, DeMarie S, Graybill JR, Yamaguchi H, Anaissie E, Caillot D New approaches to antifungal chemotherapy. Med Mycol. 36:1998;194-206.
9. Walsh TJ, Yeldandi V, McEvoy M, Gonzalez C, Chanock S, Freifeld A, Seibel NI, Whitcomb PO, Jarosinski P, Boswell Get al. Safety, tolerance and pharmacokinetics of a small unilamellar liposomal formulation of smphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother. 42:1998;2391-2398.
10. Boswell GW, Buell D, Bekersky I AmBisome (Liposomal Amphotericin B): a comparative review. J Clin Pharmacol. 38:1998;583-592. An interesting review of the liposomal formulations of amphotericin B and their efficacy.
11. Swenson CE, Perkin WR, Roberts P, Ahmad I, Stevens R, Stevens DA, Janoff AS In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important? Antimicrob Agents Chemother. 42:1998;767-771.
12. Johnson EM, Ojwang JO, Szekely A, Wallace TL, Denning DW Comparison in in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob Agents Chemother. 42:1998;1412-1416.
13. Oakley KL, Moore CB, Denning DW Comparison of in vitro ativity of liposomal nystatin (Nyotran) against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole. Antimicrob Agents Chemother. 43:1999;1246-1264.
14. Vanden Bossche H, Dromer F, Improvisi I, Lozano-Chiu M, Rex JH, Sanglard D Antifungal drug resistance in pathogenic fungi. Med Mycol. 36(suppl 1):1998;119-128.
15. Oakley KL, Moore CB, Denning DW In vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. J Antimicrob Chemother. 42:1998;91-94.
16. Wildfeuer A, Seidl HP, Paule I, Haberreiter A In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin. Mycoses. 41:1998;309-319.
17. McGinnis MR, Pasarell L, Sutton DA, Fothergill AW, Coooper CR, Rinaldi MG In vitro activity of voriconazole against selected fungi. Med Mycol. 36:1998;239-242.
18. Verweij PE, Mensink M, Rijs AJ, Donnelly JP, Meis JF, Denning DW In vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillju fumigatus isolates. J Antimicrob Chemother. 43:1998;389-392.
19. Fung-Tomc JC, Huczko E, Minassian B, Bonner DP In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob Agents Chemother. 42:1998;313-318.
20. Salama SM, Gandhi A, Atwal H, Simon J, Khan J, Micetich RG, Daneshtalab M Syn2869, a new potent antifungal triazole for the treatment of systemic and superficial fungal infections: in vitro activity against clinical isolates of yeast and dermatophytes. Abstracts of the 38th Annual Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27, San Diego, CA. 1998;F150 American Society for Microbiology, Washington, DC.
21. Fothergill AW, Salama SM, Rinaldi MG An in vitro heat-to-head comparison of Syn2836, Syn2869, Syn2903, Syn2921, Amphotericin B, Fluconazole and itraconazole against a spectrum of 90 clinically-significant fungi. Abstracts of the 38th Annual Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27, San Diego, CA. 1998;J177 American Society for Microbiology, Washington, DC.
22. Shock K, Marino S, Baumgartner T, Andriole V Efficacy of a new triazole, BMS-207147, in a model of invasive aspergillosis in immunosuppressed, neutropenic rabbits. Abstracts of the 38th Annual Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27, San Diego, CA. 1998;466 American Society for Microbiology.
23. Reyes G, Koul A, Jessup C, Ghannoum MA Efficacy of voriconazole in the treatment of hematogenously disseminated Candida glabrata in a neutropenic guinea pig model. Abstracts of the 38th Annual Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27, San Diego, CA. 1998;468 American Society for Microbiology, Washington, DC.
24. Loebenberg D, Menzel F, Corcoran E, Cacciapuoti AF, Hare RS Efficacy of prophylactic and therapeutic dosing of SCH56592 (SCH) and itraconazole (ITZ) against experimental pulmonary aspergillosis in mice. Abstracts of the 38th Annual Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27, San Diego, CA. 1998;469 American Society for Microbiology, Washington, DC.
25. Sorensen KN, Clemons KV, Sobel RA, Pappagianis D, Steven DA, Williams PL Efficacies of fluconazole and itraconazole in a rabbit model of Coccidioidal meningitis. Abstracts of the 38th Annual Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27, San Diego, CA. 1998;469 American Society for Microbiology, Washington, DC.
26. Graybill JR, Bocanegra R, Najvar LK, Luther MF, Loebenber D SCH 56592 treatment of murine invasive aspergillosis. J Antimicrob Chemother. 42:1998;539-542.
27. Sanche S, Najvar L, Bocanegra R, Graybill J Efficacy of voriconazole in a guinea pig model of systemic C. albicans infection caused by isolates with elevated fluconazole MICs. Abstracts of the 38th Annual Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27, San Diego, CA. 1998;473 American Society for Microbiology, Washington, DC.
28. Furukawa T, Saito H, Uji T, Nishida K, Higashitani F, Unemi N, Yamaguchi H In vivo activity of Syn2869, a novel antifungal triazole in murine models of deep mycosis. Abstracts of the 38th Annual Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27, San Diego, CA. 1998;F149 American Society for Microbiology, Washington, DC.
29. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, Brandt ME, Hajjeh RA In vitro susceptibilities of Candida blood stream isolates to the new triazole antifungal agents BMS-207147, Sch56592, and Voriconazole. Antimicrob Agents Chemother. 42:1998;3242-3244.
30. Pfaller MA, Zhang J, Messer SA, Brandt ME, Hajjeh RA, Jessup CJ, Tumberland M, Mbidde EK, Ghannoum MA In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother. 43:1999;169-171.
31. Chavez M, Strella MME, Valverde A, Bernal S, Gutierrez MJ, Quindos G, Valme HU Activity of a new antifungal voriconazole against Candida spp. Abstracts of the 38th Annual Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27, San Diego, CA. 1998;452 American Society for Microbiology, Washington, DC.
32. Ramos G, Cuenca-Estrella M, Monzon A, Martinez-Suarez JV, Rodriguez-Tudela JL In vitro comparative activity of UR-9825, fluconazole (FLZ) and itraconazole (ITR) against 254 yeast clinical isolates. Abstracts of the 38th Annual Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27, San Diego, CA. 1998;453 American Society for Microbiology, Washington, DC.
33. Cuenca-Estrella M, Ropdriguez-Tudela JL, Mellado E, Martinez-Suarez JV, Monzon A Comparison of the in vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother. 42:1998;531-533.
34. Nguyen MH, Yu CY Voriconazole against fluconazole-susceptible and resistant candida isolates: in vitro efficacy compared with that of itraconazole and ketoconazole. J Antimicrob Chemother. 42:1998;253-256.
35. Marco F, Pfaller MA, Messer SA, Jones RN In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi. Mycopathol. 141:1998;73-77.
36. Takesako K, Kuroda H, Inoue T, Haruna F, Yoshikawa Y, Kato I, Uchida K, Hiratani T, Yamaguchi H Biological properties of aureobasidin A, a cyclic depsipeptide antifungal antibiotic. J Antibiot. 46:1993;1414-1420.
37. Heidler SA, Radding JA The AUR1 gene in Saccharomyces cerevisiae encodes dominant resistance to the antifungal agent aureobasidin A (LY295337). Antimicrob Agents Chemother. 39:1995;2765-2769.
38. Nagiec MM, Nagieec EE, Baltisberger JA, Wells GB, Lester RL, Dickson RC Sphingolipid synthesis as a target for antifungal drugs: complementation of the inositol phosphorylceramide synthase defect in a mutant strain of Saccharomyces cerevisiae by the AUR1 gene. J Biol Chem. 272:1997;9809-9817.
39. Mandala SM, Thornton RA, Rosenbach M, Milligan J, Garcia-Calvo M, Bull HG, Kurtz MB Khafrefungin, a novel inhibitor of sphingolipid synthesis. J Biol Chem. 272:1997;32709-32714.
40. Mandala SM, Thornton RA, Milligan J, Rosenbach M, Garcia-Calvo M, Bull HG, Harris G, Abruzzo GK, Flattery AM, Gill CJ Rustmicin, a potent antifungal agent, inhibits sphingolipid synthesis at inositol phosphoceramide synthase. J Biol Chem. 273:1998;14942-14949.
41. Hashido-Okado T, Hyasumoto R, Endo M, Takesako K, Kato I Isolation and characterization of the aureobasidin A-resistant gene, aur1R, on Schizsaccharomyces pombe: roles of Aur1p+ in cell morphogenesis. Curr Genet. 33:1998;38-45.
42. Kuroda M, Hashida-Okado T, Yasumoto R, Kato GK, Takesako K An aureobasidin A resistance gene isolated from Aspergillus is a homolog of yeast AUR1 , a gene responsible for inositol phosphrylceramide (IPC) synthase activity. Mol Gen Genet. 261:1999;290-296.
43. Georgopapadakou NH Antifungals targeted to the cell wall. Exp Opin Invest Drugs. 6:1997;147-150.
44. Denning DW Echinocandins and pneumocandins - a new antifungal class with a novel mode of action. J Antimicrob Chemother. 40:1997;611-614.
45. Douglas CM, D'Ippolito JA, Shei GJ, Meinz MO, Marrinan JA, Li W, Abruzzo GK, Flattery A, Bartizal K, Mitchell A, Kurtz MB Identification fo the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother. 41:1997;2471-2479.
46. Douglas CM, Marrinan JA, Li W, Kurtz MB A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-β-D-glucan synthase. J Bacteriol. 176:1994;5686-5696.
47. Radding JA, Heidler SA, Turner WW Photoaffinity analog of the semisynthetic echinocandin LY303366: identification of echinocandin targets in Candida albicans. Antimicrob Agents Chemother. 42:1998;1187-1194. This paper identifies other proteins as potentially interacting with the echino/pneumocandins.
48. Oakley KL, Moore CB, Denning DW In vitro activity of the echinocandin antifungal agent LY303,366 in comparision with itraconazole and amphotericin B against Aspergillus spp. Antimicrob Agents Chemother. 42:1998;2726-2730.
49. Espinel-Ingroff A Comparison of in vitro activities of the new triazole SCH 56592 and the echinocandins MK-0991 (L-743,872) and LY 303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol. 36:1998;2950-2956.
50. Petriaitis V, Petraitiene R, Groll AH, Bell A, Callender DP, Sein R, Schaufele RL, McMillian CL, Bacher J, Walsh TJ Antifungal efficacy, safety and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother. 42:1998;2898-2905.
51. Verweij PE, Oakley KL, Morrissey J, Morrissey G, Denning DW Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in murine model of invasive aseprgillosis. Antimicrob Agents Chemother. 42:1998;873-878.
52. Marco F, Pfaller MA, Messer SA, Jones RN Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents testes against blood stream isolates of Candida spp. Diagn Microbiol Infect Dis. 32:1998;33037.
53. Bartizal K, Gill CJ, Abruzzo GK, Flattery AM, Kong L, Scott PM, Smith JG, Leighton CE, Bouffard A, Dropinski JF, Balkovec J In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)zzz. Antimicrob Agents Chemother. 42:1997;2326-2332.
54. Ernst EJ, Klepser ME, Ernst ME, Messer SA, Pfaller MA In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn Microbiol Infect Dis. 33:1999;75-80.
55. Pfaller MA, Marco F, Messer SA, Jones RN In vitro activity of two echinocandin derivatives, LY303366 and MK0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis. 30:1998;251-255.
56. Abruzzo GK, Flattery AM, Gill CJ, Kong L, Smith JG, Pikounis VB, Balkovec JM, Bouffard AF, Dropsinski JF, Rosen Het al. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis and cryptococcosis. Antimicrob Agents Chemother. 41:1997;2333-2338.
57. Powles MA, Liberator P, Anderson J, Karkhanis Y, Dropinski JF, Bouffard FA, Balkovec JM, Fujioka H, Aikawa M, McFadden D, Schmatz D Efficacy of MK-0991 (L-743, 872), a semisynthetic pneumocandin, in murine models of Pneumocystic carinii. Antimicrob Agents Chemother. 42:1998;1985-1989.
58. Graybill JR, Najvar LK, Montalbo EM, Barchiesi FJ, Luther MF, Rinaldi MG Treatment of histoplasmosis with MK-0991 (L-743, 872). Antimicrob Agents Chemother. 42:1998;151-153.
59. Maki K, Morishita Y, Iguchi Y, Kuwahara S In vitro antifungal activity of FK463, a novel water-soluble echinocandin-like lipopeptide. Abstracts of the 38th Annual Interscience Conference Antimicrobial Agents and Chemotherapy: 1998 Sept 24-27, San Diego, CA. 1998;F141 American Society for Microbiology, Washington DC.
60. Matsunoto S, Wakai Y, Maki K, Watabe T, Kuwahara S Efficacy of FK463, a novel water-soluble echinocandin-like lipopeptide in murine models of disseminated candidiasis. Abstracts of the 38th Annual Interscience Conference Antimicrobial Agents and Chemotherapy: 1998 Sept 24-27, San Diego, CA. 1998;F142 American Society for Microbiology, Washington DC.
61. Wakai Y, Matsumoto S, Makai K, Watabe K, Kuwahara S Efficacy of FK463, a novel water-soluble echinocandin-like lipopeptide, in murine models of pulmonary aspergillosis. Abstracts of the 38th Annual Interscience Conference Antimicrobial Agents and Chemotherapy: 1998 Sept 24-27, San Diego, CA. 1998;F143 American Society for Microbiology, Washington DC.
62. Gaughran JP, Lai MH, Kirsch DR, Silverman SJ Nikkomycin Z is a specific inhibitor of Saccharomyces cerevisiae chitin synthase isozyme Chs3 in vitro and in vivo. J Bacteriol. 176:1994;5857-5860.
63. Li RK, Rinaldi MG In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole. Antimicrob Agents Chemother. 43:1999;1401-1405.
64. Clemons KV, Stevens DA Efficacy of nikkomycin Z against experimental pulmonary blastomycosis. Antimicrob Agents Chemother. 41:1997;2026-2068.
65. Graybill JR, Najvar LK, Bocanegra R, Hector RF, Luther MF Efficacy of Nikkomycin Z ion the treatment of murine histoplasmosis. Antimicrob Agents Chemother. 42:1998;2371-2374.
66. Watanabe M, Gomi S, Tohyama H, Ohtsuka K, Shibahara S, Inouye S, Kobayashi H, Suzuki S, Kondo S, Takeuchi T, Yamaguchi H Binding of benanomicin A to fungal cells in reference to its fungicidal action. J Antibiot. 49:1996;366-373.
67. Oki T, Kakushima M, Hirano M, Takahashi A, Ohta S, Masuyoshi S, Hatori M, Kamei H In vitro and in vivo antifungal activities of BMS-181184. J Antibiot. 25:1992;1512-1517.
68. Restrepo MI, Najvar LK, Fothergill AW, Graybill JR Pradimicin therapy of disseminated Candida tropicalis infection in the mouse. Med Mycol. 36:1998;181-184.
69. Gonzalez CE, Groll AH, Giri N, Shetty D, Al-Mohsen I, Feuerstein E, Bacher J, Piscitelli S, Walsh TJ Antifungal activity of the pradimicin derivative BMS 181184 in the treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother. 42:1998;2399-2404.
70. Walsh TJ, Giri N Pradimicins: a novel class of broad-spectrum antifungal compounds. Eur J Clin Microbiol Infect Dis. 16:1997;93-97.
71. Sandbaken MG, Lupisella JA, DiDomenico B, Chakraburtty K Protein synthesis in yeast: structural and functional analysis of the gene encoding elongation factor 3. J Biol Chem. 265:1990;15838-15844.
72. DiDomenico BJ, Lupisella J, Sandbaken M, Chakraburtty K Isolation and sequence analysis of the gene encoding translation elongation factor 3 from Candida albicans. Yeast. 8:1992;337-352.
73. Uritani M, Shoumura Y, Yamada S Detection and analysis of translation elongation factor 3 genes from various yeasts. Biosci Biotechnol Biochem. 63:1999;769-772.
74. Herreros E, Martinez CM, Almela MJ, Marriott MS, Gomez de las Heras F, Gargallo-Viola D Sordarin: in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii , and filamentous fungi. Antimicrob Agents Chemother. 42:1998;2863-2869.
75. Aviles P, Aliouat EM, Martinez A, San Roman R, Guillen MJ, Ferrer S, Gomez de las Heras F, Gargallo-Viola D Pharmacokinetic/Pharmacodynamic (PK/PD) study of sordarin derivative against Pneumocystis carinii pneumonia in a corticosteroid-treated rat model. Abstracts of the 38th Annual Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27, San Diego, CA. 1998;J56 American Society for Microbiology, Washington DC.
76. Capa L, Mendoza A, Lavandera JL, Gomez de las Heras F, Garcia-Bustos J Translation elongation factor 2 is part of the target for a new family of antifungals. Antimicrob Agents Chemother. 42:1998;2694-2699.
77. Justice MC, Hsu M-J, Tse B, Ku T, Balkovec J, Schmatz D, Nielsen J Elongation factor 2 as a novel target for selective inhibition of fungal protein synthesis. J Biol Chem. 273:1998;3148-3151.
78. Dominguez JM, Martin JJ Identification of elongation factor 2 as the essential protein targeted by sordarins in Candida albicans. Antimicrob Agents Chemother. 42:1998;2279-2283. This paper first identified EF2 as the soluble factor from Candida as binding to sordarin.
79. Justice MC, Ku T, Hsu MJ, Carniol K, Schmatz D, Nielsen JL Mutations in ribosomal protein L10e confer resistance to the fungal-specific eukaryotic elongation factor 2 inhibitor sordarin. J Biol Chem. 274:1999;4869-4875. This paper suggests that sordarins may interact with other ribosomal proteins to enhance specificity.
80. Gomez-Lorenzo MG, Garcia-Bustos JF Ribosomal P-protein stalk function is targeted by sordarin antifungals. J Biol Chem. 273:1998;25041-25044.
81. Langner CA, Lodge JK, Travis SJ, Caldwell JE, Lu T, Li Q, Bryant ML, Devadas B, Gokel GW, Kobayashi GS, Gordon JI Oxatetradecanoic acid is fungicidal for Cryptococcus neoformans and inhibits replication of human immunodeficiency virus I. J Biol Chem. 267:1992;17159-17169.
82. Lodge JK, Jackson-Machelski E, Toffaletti KL, Perfect JR, Gordon JI Targeted gene replacement demonstrates that myristoyl-CoA:protein N-myristoyltransferase is essential for viability of Cryptococcus neoformans. Proc Natl Acad Sci USA. 91:1994;12008-12012.
83. Weinberg RA, McWherter CA, Freeman SK, Wood DC, Gordon JI, Lee SC Genetic studies reveal that myristoylCoA:protein N-myristoyltransferase is an essential enzyme in Candida albicans. Mol Microbiol. 6:1995;241-250.
84. Lodge JK, Hohnson RL, Weinberg RA, Gordon JI Comparison of myristoyl CoA:protein N-myristoyltransferases from three pathogenic fungi - Cryptococcus neoformans, Histoplasma capsulatum, and Candida albicans. J Biol Chem. 269:1994;2996-3009.
85. Saccharomyces Genome Database on World Wide Web URL: http://genome-www.stanford.edu/Saccharomyces.
86. Devadas B, Freeman SK, Zupec ME, Lu HF, Nagarajan SR, Kishore NS, Lodge JK, Luneman DW, McWherter CA, Vinjamoori DVet al. Design and synthesis of novel imidazole-substituted dipeptide amides as potent and selective inhibitors of Candida albicans myristoylCoA:protein N-myristoyltransferase and identification of related tripeptide inhibtors with mechanism-based antifungal activity. J Med Chem. 40:1997;2609-2625.
87. Devadas B, Freeman SK, McWherter CA, Kishore NS, Lodge JK, Jackson-Machelski E, Gordon JI, Sikorski JA Novel biologically active nonpeptidic inhibitors of myristoylCoA:protein N-myristoyltransferase. J Med Chem. 41:1998;996-1000. This paper describes non-peptidomimetic inhibitors of NMT1 that are active in vitro.
88. Weston SA, Camble R, Colls JR, Taylor I, Egerton M, Tucker AD, Tunnicliffe A, Mistry A, Mancia Fet al. Crystal structure of the anti-fungal target N-myristoyl transferase. Nat Struct Biol. 5:1998;213-221.
89. Candida albicans Information on World Wide Web URL: http://alces.med.umn.edu/Candida.html.
90. Fungal Genome Resource on World Wide Web URL: http://fungus.genetics.uga.edu:5080/.
91. Cryptococcus neoformans cDNA Sequencing on World Wide Web URL: http://www.genome.ou.edu/cneo.html.
92. Fusarium sporotrichioides cDNA Sequencing on World Wide Web UTL: http://www.genome.ou.edu/fsporo.html.